HORIZONS trial: A step forward for primary percutaneous coronary intervention

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 2, 2009, Pages 125-129

  White, Harvey D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

HORIZONS; Myocardial infarction; Primary percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; PACLITAXEL; PRASUGREL; TICLOPIDINE; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART CATHETERIZATION; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; STROKE; THROMBUS; UNSTABLE ANGINA PECTORIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FOLLOW UP; RANDOMIZED CONTROLLED TRIAL; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; STENTS;

EID: 64749114485     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.2.125     Document Type: Article

References (25)

1. Bittl JA, Strony J, Brinker JA et al.; the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction. angina. N. Engl. J. Med. 333(12), 764-769 (1995).
2. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7), 853-863 (2003).
3. Lincoff AM, Kleiman NS, Kereiakes DJ et al.; the REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292(6), 696-703 (2004).
4. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 355(21), 2203-2216 (2006).
5. Kastrati A, Neumann FJ, Mehilli J et al.; the ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N. Engl. J. Med. 359(7), 688-696 (2008).
6. Stone GW, Witzenbichler B, Guagliumi G et al.; the HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358(21), 2218-2230 (2008).
7. Antman EM, Hand M, Armstrong PW et al. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117(2), 296-329 (2008).
8. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 29, 2909-2945 (2008).
9. Fox KA, Steg PG, Eagle KA et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297(17), 1892-1900 (2007).
10. Dauerman HL, Frederick PD, Miller D, French WJ. Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. Coron. Artery Dis. 18(2), 141-148 (2007).
11. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8), 774-782 (2006).
12. Feit F, Voeltz MD, Attubato MJ et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am. J. Cardiol. 100(9), 1364-1369 (2007).
13. Kinnaird TD, Stabile E, Mintz GS et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am. J. Cardiol. 92(8), 930-935 (2003).
14. Manoukian SV, Feit F, Mehran K et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients, with acute coronary syndromes: an analysis from the ACUITY Trial. J. Am. Coll. Cardiol. 49(12), 1362-1368 (2007).
15. Ndrepepa G, Berger PB, Mehilli J et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J. Am. Coll. Cardiol. 51(7), 690-697 (2008).
16. Rao SV, Jollis JG, Harrington RA et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292(13), 1555-1562 (2004).
17. Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354(14), 1464-1476 (2006).
18. Topol EJ, Califf RM, Weisman HF et al.; on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343, 881-886 (1994).
19. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 336(24), 1689-1696 (1997).
20. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-Plus) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. 338(21), 1488-1497 (1998).
21. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl. J. Med. 338(21), 1498-1505 (1998).
22. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med. 339(7), 436-443 (1998).
23. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007).
24. Greenbaum AB, Ohman EM, Gibson CM et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am. Heart J. 154(4), 702-709 (2007).
25. White HD, Chew DP, Hoekstra JW et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. J. Am. Coll. Cardiol. 51(18), 1734-1741 (2008).